Michaël J.B. van Baar

1.1k total citations · 2 hit papers
12 papers, 773 citations indexed

About

Michaël J.B. van Baar is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Nephrology. According to data from OpenAlex, Michaël J.B. van Baar has authored 12 papers receiving a total of 773 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Surgery and 5 papers in Nephrology. Recurrent topics in Michaël J.B. van Baar's work include Diabetes Treatment and Management (10 papers), Chronic Kidney Disease and Diabetes (5 papers) and Pancreatic function and diabetes (5 papers). Michaël J.B. van Baar is often cited by papers focused on Diabetes Treatment and Management (10 papers), Chronic Kidney Disease and Diabetes (5 papers) and Pancreatic function and diabetes (5 papers). Michaël J.B. van Baar collaborates with scholars based in Netherlands, Canada and United States. Michaël J.B. van Baar's co-authors include Daniël H. van Raalte, Marcel H.A. Muskiet, Jaap A. Joles, Mark H.H. Kramer, Ewout J. Hoorn, Lennart Tonneijck, Mark M. Smits, Richard G. IJzerman, Charlotte C. van Ruiten and Liselotte van Bloemendaal and has published in prestigious journals such as Diabetes Care, Kidney International and Nature Reviews Nephrology.

In The Last Decade

Michaël J.B. van Baar

11 papers receiving 764 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

2017 294 citations Marcel H.A. Muskiet, Lennart Tonneijck et al. Nature Reviews Nephrology profile →
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

2019 253 citations Erik J.M. van Bommel, Marcel H.A. Muskiet et al. Kidney International profile →

Peers

Michaël J.B. van Baar

EDM

SURGE

NEPHR

PHARM

Claire C. J. Dekkers Netherlands

Norm Rosenthal United States

Audrey Koitka‐Weber Germany

Elke Seewaldt-Becker Germany

Nobuko Maruyama Japan

Zin Zin Htike United Kingdom

Ryo Kodera Japan

Josselin Nespoux United States

Markus F. Scheerer Germany

Claire C. J. Dekkers Netherlands

Michaël J.B. van Baar

599 ×0.9

EDM

319 ×1.0

SURGE

210 ×0.9

228 ×1.4

NEPHR

74 ×0.7

PHARM

Citations per year, relative to Michaël J.B. van Baar Michaël J.B. van Baar (= 1×) peers Claire C. J. Dekkers

Countries citing papers authored by Michaël J.B. van Baar

Since Specialization

Citations

This map shows the geographic impact of Michaël J.B. van Baar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michaël J.B. van Baar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michaël J.B. van Baar more than expected).

Fields of papers citing papers by Michaël J.B. van Baar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michaël J.B. van Baar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michaël J.B. van Baar. The network helps show where Michaël J.B. van Baar may publish in the future.

Co-authorship network of co-authors of Michaël J.B. van Baar

This figure shows the co-authorship network connecting the top 25 collaborators of Michaël J.B. van Baar. A scholar is included among the top collaborators of Michaël J.B. van Baar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michaël J.B. van Baar. Michaël J.B. van Baar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Baar, Michaël J.B. van, Marcel H.A. Muskiet, Daan J. Touw, et al.. (2025). Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes ( RACELINES ): A randomised, double‐blind trial. Diabetes Obesity and Metabolism. 27(7). 3943–3956.

Baar, Michaël J.B. van, Erik J.M. van Bommel, Daan J. Touw, et al.. (2023). Acute Effects of Insulin Infusion on Kidney Hemodynamic Function in People With Type 2 Diabetes and Normal Kidney Function. Kidney International Reports. 8(4). 916–920. 1 indexed citations

Baar, Michaël J.B. van, Erik J.M. van Bommel, Mark M. Smits, et al.. (2022). Whole-body insulin clearance in people with type 2 diabetes and normal kidney function: Relationship with glomerular filtration rate, renal plasma flow, and insulin sensitivity. Journal of Diabetes and its Complications. 36(4). 108166–108166. 1 indexed citations

Baar, Michaël J.B. van, et al.. (2020). Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors. Nephrology. 26(5). 377–390. 12 indexed citations

Bommel, Erik J.M. van, Marcel H.A. Muskiet, Michaël J.B. van Baar, et al.. (2019). The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney International. 97(1). 202–212. 253 indexed citations breakdown →

Baar, Michaël J.B. van & Daniël H. van Raalte. (2019). Renoprotection in diabetic kidney disease. Current Opinion in Nephrology & Hypertension. 29(1). 103–111. 1 indexed citations

Bommel, Erik J.M. van, Marcel H.A. Muskiet, Michaël J.B. van Baar, et al.. (2019). Insulin Sensitivity and Renal Hemodynamic Function in Metformin-Treated Adults With Type 2 Diabetes and Preserved Renal Function. Diabetes Care. 43(1). 228–234. 16 indexed citations

Baar, Michaël J.B. van, Yuliya Lytvyn, Petter Bjornstad, et al.. (2019). Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?. Diabetes Obesity and Metabolism. 21(S2). 24–33. 19 indexed citations

Baar, Michaël J.B. van, et al.. (2019). The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists. Therapeutic Advances in Endocrinology and Metabolism. 10. 2388785974–2388785974. 26 indexed citations

10.

Baar, Michaël J.B. van, Charlotte C. van Ruiten, Marcel H.A. Muskiet, et al.. (2018). SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care. 41(8). 1543–1556. 144 indexed citations

11.

Muskiet, Marcel H.A., Lennart Tonneijck, Mark M. Smits, et al.. (2017). GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nature Reviews Nephrology. 13(10). 605–628. 294 indexed citations breakdown →

12.

Turner, Patricia V., Michaël J.B. van Baar, & Ernest D. Olfert. (2009). Laboratory animal medicine - needs and opportunities for Canadian veterinarians.. PubMed. 50(3). 257–60. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact